Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 792187, 9 pages
http://dx.doi.org/10.1155/2015/792187
Review Article

B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia

1Department of Pediatric Oncology, University Hospital and Faculty of Medicine, Masaryk University, Cernopolni 9, 613 00 Brno, Czech Republic
2Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno, Czech Republic
3Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
4Advanced Cell Immunotherapy Unit, Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic

Received 22 October 2014; Accepted 28 April 2015

Academic Editor: Olive Joy Wolfe

Copyright © 2015 Michal Rihacek et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H.-B. Shu, W.-H. Hu, and H. Johnson, “TALL-1 is a novel member of the TNF family that is down-regulated by mitogens,” Journal of Leukocyte Biology, vol. 65, no. 5, pp. 680–683, 1999. View at Google Scholar · View at Scopus
  2. B. B. Aggarwal, S. C. Gupta, and J. H. Kim, “Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey,” Blood, vol. 119, no. 3, pp. 651–665, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Mackay and J. L. Browning, “BAFF: a fundamental survival factor for B cells,” Nature Reviews. Immunology, vol. 2, no. 7, pp. 465–475, 2002. View at Publisher · View at Google Scholar
  4. B. Schiemann, J. L. Gommerman, K. Vora et al., “An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway,” Science, vol. 293, no. 5537, pp. 2111–2114, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. J. A. Gross, S. R. Dillon, S. Mudri et al., “TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS,” Immunity, vol. 15, no. 2, pp. 289–302, 2001. View at Publisher · View at Google Scholar
  6. E. Castigli, S. A. Wilson, S. Scott et al., “TACI and BAFF-R mediate isotype switching in B cells,” The Journal of Experimental Medicine, vol. 201, no. 1, pp. 35–39, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. J. E. Stadanlick, M. Kaileh, F. G. Karnell et al., “Tonic B cell antigen receptor signals supply an NF-κB substrate for prosurvival BLyS signaling,” Nature Immunology, vol. 9, no. 12, pp. 1379–1387, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Bossen and P. Schneider, “BAFF, APRIL and their receptors: structure, function and signaling,” Seminars in Immunology, vol. 18, no. 5, pp. 263–275, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. J. S. Thompson, S. A. Bixler, F. Qian et al., “BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF,” Science, vol. 293, no. 5537, pp. 2108–2111, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Yan, J. R. Brady, B. Chan et al., “Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency,” Current Biology, vol. 11, no. 19, pp. 1547–1552, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Bossen, T. G. Cachero, A. Tardivel et al., “TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts,” Blood, vol. 111, no. 3, pp. 1004–1012, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Seshasayee, P. Valdez, M. Yan et al., “Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor,” Immunity, vol. 18, no. 2, pp. 279–288, 2003. View at Publisher · View at Google Scholar
  13. Johns Hopkins University, Online Mendelian Inheritance in Man, OMIM, Johns Hopkins University, Baltimore, Md, USA, 2012, http://omim.org/.
  14. B. P. Deng, Y. Zhang, Q. J. Wang et al., “Soluble BAFF-R produced by decidual stromal cells plays an inhibitory role in monocytes and macrophages,” Reproductive Biomedicine Online, vol. 24, no. 6, pp. 654–663, 2012. View at Publisher · View at Google Scholar
  15. S. J. Rodig, A. Shahsafaei, B. Li, C. R. Mackay, and D. M. Dorfman, “BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders,” Human Pathology, vol. 36, no. 10, pp. 1113–1119, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. Q. Ye, L. Wang, A. D. Wells et al., “BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses,” European Journal of Immunology, vol. 34, no. 10, pp. 2750–2759, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. V.-I. Alexaki, G. Notas, V. Pelekanou et al., “Adipocytes as immune cells: differential expression of TWEAK, BAFF, and APRIL and their receptors (Fn14, BAFF-R, TACI, and BCMA) at different stages of normal and pathological adipose tissue development,” The Journal of Immunology, vol. 183, no. 9, pp. 5948–5956, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Fu, Y.-C. Lin-Lee, L. V. Pham, A. T. Tamayo, L. C. Yoshimura, and R. J. Ford, “BAFF-R promotes cell proliferation and survival through interaction with IKKβ and NF-κB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells,” Blood, vol. 113, no. 19, pp. 4627–4636, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. R. H. Carter, H. Zhao, X. Liu et al., “Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 52, no. 12, pp. 3943–3954, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. J.-O. Pers, C. Daridon, V. Devauchelle et al., “BAFF overexpression is associated with autoantibody production in autoimmune diseases,” Annals of the New York Academy of Sciences, vol. 1050, pp. 34–39, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. Johns Hopkins University, Online Mendelian Inheritance in Man, OMIM, Johns Hopkins University, Baltimore, Md, USA, 2011, http://omim.org/.
  22. R. Wang, N. Ma, Y. Guo et al., “Identify the key amino acid of BAFF binding with TACI,” Cellular Immunology, vol. 284, no. 1-2, pp. 84–90, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Wang, S. A. Marsters, T. Baker et al., “TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice,” Nature Immunology, vol. 2, no. 7, pp. 632–637, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Yan, S. A. Marsters, I. S. Grewal, H. Wang, A. Ashkenazi, and V. M. Dixit, “Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity,” Nature Immunology, vol. 1, no. 1, pp. 37–41, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Yu, T. Boone, J. Delaney et al., “APRIL and TALL-I and receptor BCMA and TACI: system for regulating humoral immunity,” Nature Immunology, vol. 1, no. 3, pp. 252–256, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. A. E. J. Poodt, G. J. A. Driessen, A. de Klein, J. J. M. van Dongen, M. van Der Burg, and E. de Vries, “TACI mutations and disease susceptibility in patients with common variable immunodeficiency,” Clinical and Experimental Immunology, vol. 156, no. 1, pp. 35–39, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. U. Salzer, H. M. Chapel, A. D. B. Webster et al., “Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans,” Nature Genetics, vol. 37, no. 8, pp. 820–828, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. Online Mendelian Inheritance in Man, OMIM, Johns Hopkins University, Baltimore, Md, USA, MIM Number: 109545, 2012, http://omim.org/.
  29. B. P. O'Connor, V. S. Raman, L. D. Erickson et al., “BCMA is essential for the survival of long-lived bone marrow plasma cells,” Journal of Experimental Medicine, vol. 199, no. 1, pp. 91–97, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. A. J. Novak, J. R. Darce, B. K. Arendt et al., “Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival,” Blood, vol. 103, no. 2, pp. 689–694, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Moreaux, E. Legouffe, E. Jourdan et al., “BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone,” Blood, vol. 103, no. 8, pp. 3148–3157, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. R. O. Carpenter, M. O. Evbuomwan, S. Pittaluga et al., “B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma,” Clinical Cancer Research, vol. 19, no. 8, pp. 2048–2060, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Sasaki, E. Derudder, E. Hobeika et al., “Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation,” Immunity, vol. 24, no. 6, pp. 729–739, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. J.-I. Inoue, T. Ishida, N. Tsukamoto et al., “Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling,” Experimental Cell Research, vol. 254, no. 1, pp. 14–24, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Schneider, F. Mackay, V. Steiner et al., “BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth,” Journal of Experimental Medicine, vol. 189, no. 11, pp. 1747–1756, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. B. Nardelli, O. Belvedere, V. Roschke et al., “Synthesis and release of B-lymphocyte stimulator from myeloid cells,” Blood, vol. 97, no. 1, pp. 198–204, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Kreuzaler, M. Rauch, U. Salzer et al., “Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors,” Journal of Immunology, vol. 188, no. 1, pp. 497–503, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. P. A. Moore, O. Belvedere, A. Orr et al., “BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator,” Science, vol. 285, no. 5425, pp. 260–263, 1999. View at Publisher · View at Google Scholar
  39. Y.-H. Kim, B.-H. Choi, H.-G. Cheon, and M.-S. Do, “B cell activation factor (BAFF) is a novel adipokine that links obesity and inflammation,” Experimental and Molecular Medicine, vol. 41, no. 3, pp. 208–216, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Hamada, M. Abe, T. Miyake et al., “B cell-activating factor controls the production of adipokines and induces insulin resistance,” Obesity, vol. 19, no. 10, pp. 1915–1922, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. A. K. Knight, L. Radigan, T. Marron, A. Langs, L. Zhang, and C. Cunningham-Rundles, “High serum levels of BAFF, APRIL, and TACI in common variable immunodeficiency,” Clinical Immunology, vol. 124, no. 2, pp. 182–189, 2007. View at Publisher · View at Google Scholar
  42. A. Davidson, “Targeting BAFF in autoimmunity,” Current Opinion in Immunology, vol. 22, no. 6, pp. 732–739, 2010. View at Publisher · View at Google Scholar
  43. R. S. Ahima and S. Y. Osei, “Adipokines in obesity,” Frontiers of Hormone Research, vol. 36, pp. 182–197, 2008. View at Publisher · View at Google Scholar
  44. G. Ferraccioli and E. Gremese, “Adiposity, joint and systemic inflammation: the additional risk of having a metabolic syndrome in rheumatoid arthritis,” Swiss Medical Weekly, vol. 141, Article ID w13211, 2011. View at Publisher · View at Google Scholar
  45. H. Xu, X. He, Y. Zhu, T. Yan, H. Ma, and X. Zhang, “Abnormally high expression of BAFF on T lymphocytes from lung cancer-associated pleural effusions and its potent anti-tumor effect,” Acta Biochimica et Biophysica Sinica, vol. 39, no. 12, pp. 964–973, 2007. View at Google Scholar · View at Scopus
  46. S.-J. Woo, J. Im, J. H. Jeon et al., “Induction of BAFF expression by IFN-γ via JAK/STAT signaling pathways in human intestinal epithelial cells,” Journal of Leukocyte Biology, vol. 93, no. 3, pp. 363–368, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Zhou, R. Zhong, W. Hao et al., “Interleukin-10 and interferon-γ up-regulate the expression of B-cell activating factor in cultured human promyelocytic leukemia cells,” Experimental and Molecular Pathology, vol. 87, no. 1, pp. 54–58, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Ittah, C. Miceli-Richard, J.-E. Gottenberg et al., “B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome,” Arthritis Research and Therapy, vol. 8, no. 2, article R51, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. P. Scapini, F. Bazzoni, and M. A. Cassatella, “Regulation of B-cell-activating factor (BAFF)/B lymphocyte stimulator (BLyS) expression in human neutrophils,” Immunology Letters, vol. 116, no. 1, pp. 1–6, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. K. S. Gandhi, F. C. McKay, S. D. Schibeci et al., “BAFF is a biological response marker to IFN-β treatment in multiple sclerosis,” Journal of Interferon and Cytokine Research, vol. 28, no. 9, pp. 529–539, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. C. J. Hedegaard, F. Sellebjerg, M. Krakauer, D. Hesse, K. Bendtzen, and C. H. Nielsen, “Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production,” Multiple Sclerosis, vol. 17, no. 5, pp. 567–577, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Panchanathan and D. Choubey, “Murine BAFF expression is up-regulated by estrogen and interferons: implications for sex bias in the development of autoimmunity,” Molecular Immunology, vol. 53, no. 1-2, pp. 15–23, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. E. Peeva, J. Venkatesh, and B. Diamond, “Tamoxifen blocks estrogen-induced B cell maturation but not survival,” Journal of Immunology, vol. 175, no. 3, pp. 1415–1423, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. T. D. Gilmore, “Introduction to NF-κB: players, pathways, perspectives,” Oncogene, vol. 25, no. 51, pp. 6680–6684, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. M. S. Hayden, A. P. West, and S. Ghosh, “NF-κB and the immune response,” Oncogene, vol. 25, no. 51, pp. 6758–6780, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. P. P. Tak and G. S. Firestein, “NF-κB: a key role in inflammatory diseases,” The Journal of Clinical Investigation, vol. 107, no. 1, pp. 7–11, 2001. View at Publisher · View at Google Scholar · View at Scopus
  57. J. M. Hildebrand, Z. Luo, M. K. Manske et al., “A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling,” Journal of Experimental Medicine, vol. 207, no. 12, pp. 2569–2579, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. X. Shen, W. Zhu, X. Zhang, G. Xu, and S. Ju, “A role of both NF-kappaB pathways in expression and transcription regulation of BAFF-R gene in multiple myeloma cells,” Molecular and Cellular Biochemistry, vol. 357, no. 1-2, pp. 21–30, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. G. Brandi, M. A. Pantaleo, G. Biasco, and P. Paterini, “Activated NF-kB in colorectal cancer: predictive or prognostic factor?” Journal of Clinical Oncology, vol. 26, no. 8, pp. 1388–1389, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. E. Pikarsky, R. M. Porat, I. Stein et al., “NF-κB functions as a tumour promoter in inflammation-associated cancer,” Nature, vol. 431, no. 7007, pp. 461–466, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. B. Baumann, J. Seufert, F. Jakob et al., “Activation of NF-κB signalling and TNFα-expression in THP-1 macrophages by TiAlV- and polyethylene-wear particles,” Journal of Orthopaedic Research, vol. 23, no. 6, pp. 1241–1248, 2005. View at Publisher · View at Google Scholar · View at Scopus
  62. J. F. Treml, Y. Hao, J. E. Stadanlick, and M. P. Cancro, “The BLyS family: toward a molecular understanding of B cell homeostasis,” Cell Biochemistry and Biophysics, vol. 53, no. 1, pp. 1–16, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Hiscott, J. Marois, J. Garoufalis et al., “Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop,” Molecular and Cellular Biology, vol. 13, no. 10, pp. 6231–6240, 1993. View at Google Scholar · View at Scopus
  64. J. P. Cogswell, M. M. Godlevski, G. B. Wisely et al., “NF-κB regulates IL-1β transcription through a consensus NF-κB binding site and a nonconsensus CRE-like site,” Journal of Immunology, vol. 153, no. 2, pp. 712–723, 1994. View at Google Scholar · View at Scopus
  65. M. Los, H. Schenk, K. Hexel, P. A. Baeuerle, W. Droge, and K. Schulze-Osthoff, “IL-2 gene expression and NF-κB activation through CD28 requires reactive oxygen production by 5-lipoxygenase,” EMBO Journal, vol. 14, no. 15, pp. 3731–3740, 1995. View at Google Scholar · View at Scopus
  66. W. Xiao, D. R. Hodge, L. Wang, X. Yang, X. Zhang, and W. L. Farrar, “NF-κB activates IL-6 expression through cooperation with c-Jun and IL6-AP1 site, but is independent of its IL6-NFκB regulatory site in autocrine human multiple myeloma cells,” Cancer Biology & Therapy, vol. 3, no. 10, pp. 1007–1017, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. T. A. Libermann and D. Baltimore, “Activation of interleukin-6 gene expression through the NF-κB transcription factor,” Molecular and Cellular Biology, vol. 10, no. 5, pp. 2327–2334, 1990. View at Google Scholar · View at Scopus
  68. R. Crinelli, A. Antonelli, M. Bianchi et al., “Selective inhibition of NF-κB activation and TNF-alpha production in macrophages by red blood cell-mediated delivery of dexamethasone,” Blood Cells, Molecules & Diseases, vol. 26, no. 3, pp. 211–222, 2000. View at Google Scholar
  69. C. Fan, J. Yang, and J. F. Engelhardt, “Temporal pattern of NFκB activation influences apoptotic cell fate in a stimuli-dependent fashion,” Journal of Cell Science, vol. 115, no. 24, pp. 4843–4853, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. B. Kaltschmidt, C. Kaltschmidt, T. G. Hofmann, S. P. Hehner, W. Dröge, and M. L. Schmitz, “The pro- or anti-apoptotic function of NF-κB is determined by the nature of the apoptotic stimulus,” European Journal of Biochemistry, vol. 267, no. 12, pp. 3828–3835, 2000. View at Publisher · View at Google Scholar
  71. C.-Y. Wang, M. W. Mayo, R. G. Korneluk, D. V. Goeddel, and A. S. Baldwin Jr., “NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation,” Science, vol. 281, no. 5383, pp. 1680–1683, 1998. View at Publisher · View at Google Scholar · View at Scopus
  72. P. Wang, L. Qian, X. Yuan et al., “BlyS: a potential hallmark of multiple myeloma,” Frontiers in Bioscience, vol. 18, no. 1, pp. 324–331, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. V. T. Chu, A. Beller, T. T. N. Nguyen, G. Steinhauser, and C. Berek, “The long-term survival of plasma cells,” Scandinavian Journal of Immunology, vol. 73, no. 6, pp. 508–511, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. L. Bolkun, D. Lemancewicz, E. Jablonska et al., “BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma,” Annals of Hematology, vol. 93, no. 4, pp. 635–644, 2014. View at Publisher · View at Google Scholar · View at Scopus
  75. D. Lemancewicz, L. Bolkun, E. Jablonska et al., “Evaluation of TNF superfamily molecules in multiple myeloma patients: correlation with biological and clinical features,” Leukemia Research, vol. 37, no. 9, pp. 1089–1093, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. M. G. Alexandrakis, P. Roussou, C. A. Pappa et al., “Relationship between circulating BAFF serum levels with proliferating markers in patients with multiple myeloma,” BioMed Research International, vol. 2013, Article ID 389579, 6 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  77. K. Itoh and S. Hirohata, “The role of IL-10 in human B cell activation, proliferation, and differentiation,” The Journal of Immunology, vol. 154, no. 9, pp. 4341–4350, 1995. View at Google Scholar · View at Scopus
  78. E. Kovacs, “Interleukin-6 leads to interleukin-10 production in several human multiple myeloma cell lines. Does interleukin-10 enhance the proliferation of these cells?” Leukemia Research, vol. 34, no. 7, pp. 912–916, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. T. Otsuki, K. Yata, H. Sakaguchi et al., “IL-10 in myeloma cells,” Leukemia and Lymphoma, vol. 43, no. 5, pp. 969–974, 2002. View at Google Scholar · View at Scopus
  80. A. J. Novak, D. M. Grote, M. Stenson et al., “Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome,” Blood, vol. 104, no. 8, pp. 2247–2253, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. S.-H. Kuo, P.-Y. Yeh, L.-T. Chen et al., “Overexpression of B cell activating factor of TNF family (BAFF) is associated with Helicobacter pylori independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma,” Blood, vol. 112, no. 7, pp. 2927–2934, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. J. Bienertova-Vasku, P. Bienert, D. Kodytkova et al., “BAFF levels are elevated in paediatric patients with acute lymphoblastic leukaemia compared to other B-lineage neoplasms,” Journal of Hematology, vol. 1, no. 1, pp. 20–22, 2012. View at Google Scholar
  83. S. Yang, J.-Y. Li, and W. Xu, “Role of BAFF/BAFF-R axis in B-cell non-Hodgkin lymphoma,” Critical Reviews in Oncology/Hematology, vol. 91, no. 2, pp. 113–122, 2014. View at Publisher · View at Google Scholar · View at Scopus
  84. Y. Oki, G. V. Georgakis, T.-S. Migone, L. W. Kwak, and A. Younes, “Prognostic significance of serum B-lymphocyte stimulator level in Hodgkin's lymphoma,” Haematologica, vol. 92, no. 2, pp. 269–270, 2007. View at Publisher · View at Google Scholar · View at Scopus
  85. C. Tecchio, G. Nadali, P. Scapini et al., “High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma,” British Journal of Haematology, vol. 137, no. 6, pp. 553–559, 2007. View at Publisher · View at Google Scholar · View at Scopus
  86. K. Onda, K. Iijima, Y. U. Katagiri et al., “Differential effects of BAFF on B cell precursor acute lymphoblastic leukemia and Burkitt lymphoma,” International Journal of Hematology, vol. 91, no. 5, pp. 808–819, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. W. Wu, S. Li, W. Zhang, G. Ren, and Q. Dong, “A novel VHH antibody targeting the B cell-activating factor for B-cell lymphoma,” International Journal of Molecular Sciences, vol. 15, no. 6, pp. 9481–9496, 2014. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Maia, M. Pelletier, J. Ding et al., “Aberrant expression of functional baff-system receptors by malignant b-cell precursors impacts leukemia cell survival,” PLoS ONE, vol. 6, no. 6, Article ID e20787, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. R. Parameswaran, M. Lim, F. Fei et al., “Effector-mediated eradication of precursor B acute lymphoblastic leukemia with a novel Fc-engineered monoclonal antibody targeting the BAFF-R,” Molecular Cancer Therapeutics, vol. 13, no. 6, pp. 1567–1577, 2014. View at Publisher · View at Google Scholar
  90. R. Parameswaran, M. Müschen, Y.-M. Kim, J. Groffen, and N. Heisterkamp, “A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias,” Cancer Research, vol. 70, no. 11, pp. 4346–4356, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. M. Koizumi, Y. Hiasa, T. Kumagi et al., “Increased B cell-activating factor promotes tumor invasion and metastasis in human pancreatic cancer,” PLoS ONE, vol. 8, no. 8, Article ID e71367, 2013. View at Publisher · View at Google Scholar · View at Scopus
  92. V. Pelekanou, M. Kampa, M. Kafousi et al., “Expression of TNF-superfamily members BAFF and APRIL in breast cancer: immunohistochemical study in 52 invasive ductal breast carcinomas,” BMC Cancer, vol. 8, article 76, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. V. Pelekanou, G. Notas, M. Kampa et al., “BAFF, APRIL, TWEAK, BCMA, TACI and Fn14 proteins are related to human glioma tumor grade: immunohistochemistry and public microarray data meta-analysis,” PLoS ONE, vol. 8, no. 12, Article ID e83250, 2013. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Fabris, E. Tonutti, C. Panighel et al., “The role of B-lymphocyte stimulator in neuroendocrine tumors: correlation with tumor differentiation, disease status and the presence of metastases,” Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, vol. 11, no. 4, pp. 306–314, 2011. View at Publisher · View at Google Scholar · View at Scopus
  95. J. Bienertova-Vasku, A. Lungova, P. Bienert et al., “Circulating levels of B-cell activating factor in paediatric patients with malignancy with or without cancer-related cachexia,” Klinicka Onkologie, vol. 25, no. 2, pp. S58–S63, 2012. View at Google Scholar · View at Scopus
  96. H.-B. Shu and H. Johnson, “B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 16, pp. 9156–9161, 2000. View at Publisher · View at Google Scholar · View at Scopus
  97. X.-Z. Xia, J. Treanor, G. Senaldi et al., “TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation,” Journal of Experimental Medicine, vol. 192, no. 1, pp. 137–143, 2000. View at Publisher · View at Google Scholar · View at Scopus
  98. H. Sakurai, S. Suzuki, N. Kawasaki et al., “Tumor necrosis factor-α-induced IKK phosphorylation of NF-κB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway,” Journal of Biological Chemistry, vol. 278, no. 38, pp. 36916–36923, 2003. View at Publisher · View at Google Scholar · View at Scopus
  99. P. Viatour, M.-P. Merville, V. Bours, and A. Chariot, “Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation,” Trends in Biochemical Sciences, vol. 30, no. 1, pp. 43–52, 2005. View at Publisher · View at Google Scholar · View at Scopus
  100. S. C. Sun, “Controlling the fate of NIK: a central stage in noncanonical NF-kappaB signaling,” Science Signaling, vol. 3, no. 123, article pe18, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. U. Senftleben, Y. Cao, G. Xiao et al., “Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway,” Science, vol. 293, no. 5534, pp. 1495–1499, 2001. View at Publisher · View at Google Scholar · View at Scopus
  102. N. J. Solan, H. Miyoshi, E. M. Carmona, G. D. Bren, and C. V. Paya, “RelB cellular regulation and transcriptional activity are regulated by p100,” The Journal of Biological Chemistry, vol. 277, no. 2, pp. 1405–1418, 2002. View at Publisher · View at Google Scholar · View at Scopus
  103. G. S. Hotamisligil, “Mechanisms of TNF-α-induced insulin resistance,” Experimental and Clinical Endocrinology and Diabetes, vol. 107, no. 2, pp. 119–125, 1999. View at Publisher · View at Google Scholar · View at Scopus
  104. A. K. Sundgren-Andersson, P. Ostlund, and T. Bartfai, “IL-6 is essential in TNF-α-induced fever,” The American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 275, no. 6, pp. R2028–R2034, 1998. View at Google Scholar · View at Scopus
  105. K. J. Tracey, H. Wei, K. R. Manogue et al., “Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation,” The Journal of Experimental Medicine, vol. 167, no. 3, pp. 1211–1227, 1988. View at Publisher · View at Google Scholar · View at Scopus
  106. J. A. Carson and K. A. Baltgalvis, “Interleukin 6 as a key regulator of muscle mass during cachexia,” Exercise and Sport Sciences Reviews, vol. 38, no. 4, pp. 168–176, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. F. Haddad, F. Zaldivar, D. M. Cooper, and G. R. Adams, “IL-6-induced skeletal muscle atrophy,” Journal of Applied Physiology, vol. 98, no. 3, pp. 911–917, 2005. View at Publisher · View at Google Scholar · View at Scopus
  108. O. Zamir, P. O. Hasselgren, T. Higashiguchi, J. A. Frederick, and J. E. Fischer, “Tumour necrosis factor (TNF) and interleukin-1 (IL-1) induce muscle proteolysis through different mechanisms,” Mediators of Inflammation, vol. 1, no. 4, pp. 247–250, 1992. View at Publisher · View at Google Scholar
  109. P. Gulati, “Janeway's immunobiology, 7th edition by kenneth murphy, paul travers, and mark walport,” Biochemistry and Molecular Biology Education, vol. 37, no. 2, pp. 134–134, 2009. View at Publisher · View at Google Scholar
  110. A. Oliff, D. Defeo-Jones, M. Boyer et al., “Tumors secreting human TNF/cachectin induce cachexia in mice,” Cell, vol. 50, no. 4, pp. 555–563, 1987. View at Publisher · View at Google Scholar · View at Scopus
  111. A. C. Guyton and J. E. Hall, Textbook of Medical Physiology, Elsevier Science Health Science Division, Philadelphia, Pa, USA, 12 edition, 2012.
  112. R. J. E. Skipworth, G. D. Stewart, C. H. C. Dejong, T. Preston, and K. C. H. Fearon, “Pathophysiology of cancer cachexia: much more than host-tumour interaction?” Clinical Nutrition, vol. 26, no. 6, pp. 667–676, 2007. View at Publisher · View at Google Scholar · View at Scopus
  113. S. L. Dickson, E. Egecioglu, S. Landgren, K. P. Skibicka, J. A. Engel, and E. Jerlhag, “The role of the central ghrelin system in reward from food and chemical drugs,” Molecular and Cellular Endocrinology, vol. 340, no. 1, pp. 80–87, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. V. D. Dixit, E. M. Schaffer, R. S. Pyle et al., “Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells,” The Journal of Clinical Investigation, vol. 114, no. 1, pp. 57–66, 2004. View at Publisher · View at Google Scholar · View at Scopus
  115. M. A. Brach, H. J. Gruss, D. Riedel, R. Mertelsmann, and F. Herrmann, “Activation of NF-κ B by interleukin 2 in human blood monocytes,” Cell Growth & Differentiation, vol. 3, no. 7, pp. 421–427, 1992. View at Google Scholar · View at Scopus
  116. J. A. Tayek, “A review of cancer cachexia and abnormal glucose metabolism in humans with cancer,” Journal of the American College of Nutrition, vol. 11, no. 4, pp. 445–456, 1992. View at Publisher · View at Google Scholar · View at Scopus
  117. K. Kawasaki, M. Abe, F. Tada et al., “Blockade of B-cell-activating factor signaling enhances hepatic steatosis induced by a high-fat diet and improves insulin sensitivity,” Laboratory Investigation, vol. 93, no. 3, pp. 311–321, 2013. View at Publisher · View at Google Scholar · View at Scopus
  118. M. L. Asp, M. Tian, A. A. Wendel, and M. A. Belury, “Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice,” International Journal of Cancer, vol. 126, no. 3, pp. 756–763, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. M. Tsoli and G. Robertson, “Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem,” Trends in Endocrinology & Metabolism, vol. 24, no. 4, pp. 174–183, 2013. View at Publisher · View at Google Scholar · View at Scopus
  120. R. Cabal-Manzano, P. Bhargava, A. Torres-Duarte, J. Marshall, P. Bhargava, and I. W. Wainer, “Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss,” British Journal of Cancer, vol. 84, no. 12, pp. 1599–1601, 2001. View at Publisher · View at Google Scholar · View at Scopus
  121. S. Khan and M. J. Tisdale, “Catabolism of adipose tissue by a tumour-produced lipid-mobilising factor,” International Journal of Cancer, vol. 80, no. 3, pp. 444–447, 1999. View at Publisher · View at Google Scholar · View at Scopus
  122. N. P. Gullett, V. C. Mazurak, G. Hebbar, and T. R. Ziegler, “Nutritional interventions for cancer-induced cachexia,” Current Problems in Cancer, vol. 35, no. 2, pp. 58–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  123. M. Batten, C. Fletcher, L. G. Ng et al., “TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma,” The Journal of Immunology, vol. 172, no. 2, pp. 812–822, 2004. View at Publisher · View at Google Scholar · View at Scopus
  124. S. K. Chang, B. K. Arendt, J. R. Darce, X. Wu, and D. F. Jelinek, “A role for BLyS in the activation of innate immune cells,” Blood, vol. 108, no. 8, pp. 2687–2694, 2006. View at Publisher · View at Google Scholar · View at Scopus